From March 1994 to November 1994, 16 patients with high risk hematological malignancies were entered in a phase I clinical trial, designed to confirm the toxicity of cyclosporine and gamma interferon given to induce autologous graft-versus-host disease (GVHD) after autologous bone marrow transplantation (ABMT). This trial was based on the results in a rodent model, in which cyclosporine given after ABMT induces an autoimmune syndrome (autologous GVHD) identical to allogeneic GVHD. Further, this autologous GVHD is associated with a graft-versus-tumor effect augmented by interferon that upregulates MHC class II expression on normal and tumor cells, the target of the cytolytic T cells in autologous GVHD. In this trial, cyclosporine 1 mg/kg/day was given from the day of bone marrow reinfusion until the completion of the interferon and gamma-interferon. Gamma-interferon at 0.025 mg/m 2 every other day was started when the total white cell count was Ͼ200 cells/ml for 2 consecutive days and continued for a total of 10 doses after ABMT. The preparative regimens were busulfan and cyclophosphamide, or cyclophosphamide with total body irradiation. All patients received 4HC-purged marrow grafts. Median age was 45 years (range 19-68). The diagnoses included chemo-resistant non-Hodgkin's lymphoma (10), acute lymphoblastic leukemia (two), chemo-resistant Hodgkin's disease (two), acute myeloid leukemia (one), and multiple myeloma (one). Median absolute neutrophil count recovery was 25.5 days (range 19-46 days). Median platelet count recovery was 40.5 days (range 28-279 days). There were nine deaths, two were related to transplant toxicity (infection), while the other seven were due to relapse. Event-free survival with a median of 964 days (range 19-1441 days of follow-up was 44%. In conclusion, treatment with cyclosporine, and gammainterferon after ABMT was well tolerated and did not impair engraftment. Further studies with a larger number of patients are required to document any beneficial anti-tumor effect of autologous GVHD induction after ABMT.
The use of intensive chemotherapy and autologous bone marrow transplantation (ABMT) or peripheral blood stem cell transplantation has become an effective therapy in high risk lymphomas and acute leukemias with 10-50% of patients achieving durable remissions. However, relapse remains the major cause of failure, with higher relapse rates than those observed in allogeneic bone marrow transplant recipients. The difference is attributed to the lack of a graftversus-tumor effect.
1,2 Unfortunately, only 25% of patients have a suitable donor for allogeneic bone marrow transplant and the remaining patients are eligible only for an ABMT or an unrelated donor BMT. Although unrelated or mismatched related BMT are associated with potent anti-tumor effects, many patients still lack a suitable donor or are not suitable candidates. Because neoplastic cells that remain viable after the preparative regimen for ABMT represent a very highly resistant population, and current cytotoxic preparative regimens for bone marrow transplant are at or near non-hematologic dose-limiting toxicity, other non-cytotoxic approaches are needed for patients undergoing ABMT.
Immunotherapy represents an alternative modality that may complement traditional chemo/radiotherapy. More importantly, the tumor cells that have developed resistance to chemotherapy may be sensitive to immunotherapy.
Cyclosporine (CsA) can induce a syndrome similar to GVHD in rodents. [3] [4] [5] A similar, but very mild clinical syndrome resembling allogeneic graft-versus-host disease (GVHD) develops spontaneously in 5-10% of patients undergoing autologous bone marrow transplant. 6 This syndrome in humans can also be experimentally induced by CsA after autologous BMT. When compared with allogeneic GVHD, autologous GVHD is milder, only involves the skin, and is self-limited. However, histologic changes in the skin of allogeneic and autologous GVHD are identical. More interestingly, autologous GVHD could potentially produce a clinical immunological anti-tumor effect similar to the allogeneic graft-versus-tumor effect without increasing post-transplant toxicity. An anti-tumor effect has been demonstrated in the animal model. 7 This has led to a number of studies investigating the clinical induction of autologous GVHD. Jones et al 8 reported the induction of autologous GVHD by CsA in patients with lymphoma, and also showed the presence of cytotoxic post-transplant lymphocytes against pre-transplant lymphocyte targets in patients with autologous GVHD. This cytotoxic effect could be blocked by pre-incubation of target cells with antibodies against the public domain of the MHC class II antigen, the target antigen of autologous GVHD as defined in the animal model and in humans. In addition, preliminary results of a phase II trial of CsA-induced autologous GVHD in patients with intermediate or high grade non-Hodgkin's lymphomas, suggest that there may be a clinically significant anti-tumor effect. 9 In an attempt to maximize the anti-tumor effects of autologous GVHD, several cytokines have been explored. Since MHC class II is recognized in autologous GVHD, increased class II expression should lead to increased cytolytic effect. Laboratory experience shows that alpha-and gamma-interferons can increase the expression of MHC class II antigens in leukemia and lymphomas cell lines. 10 In addition, data from a syngeneic murine bone marrow transplant model 11, 12 also suggest that both alpha-and gamma-interferon increase the anti-tumor effect of CsA-induced autologous GVHD.
From the clinical standpoint, Kennedy et al 13 has already examined the effect of gamma-interferon on potentiating CsA-induced auto GVHD in autologous BMT for breast cancer. The trial showed increased severity of GVHD in patients treated with gamma-interferon and CsA after unpurged ABMT and subsequently, in patients receiving peripheral blood stem cell transplants (PBSC). The regimen was well tolerated and had no significant toxicity specifically ascribed to the addition of the cyclosporine after transplant. The current trial was undertaken to evaluate the toxicity of the CsA and gamma-interferon combination in patients with hematologic malignancies receiving 4HC-purged autologous bone marrow infusion.
Patients and methods

Patients
Patients between the ages of 18 and 65 years were eligible for inclusion in the gamma-interferon + CsA study. Patients with aggressive non-Hodgkin's lymphoma (NHL), and Hodgkin's disease (HD), who either progressed during induction therapy or failed to achieve at least a partial response (more than 50% reduction in tumor size) to conventional salvage therapy were eligible for inclusion. Patients with acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML) in early relapse or second complete remission after standard induction therapy and multiple myeloma patients who achieved at least a partial response after conventional therapy, were also considered eligible. Normal renal, cardiac, pulmonary and hematopoietic reserves, in addition to an ECOG performance status of 0 to 1, 14 were required in all patients.
Marrow processing, preparative regimens, CsA and interferon administration
Patients undergoing ABMT had their marrow harvested under general or regional anesthesia before beginning the preparative regimen. A minimum of 1.5 × 10 8 nucleated bone marrow cells/kg of body weight were collected. The mononuclear bone marrow cells were incubated with freshly dissolved 4 hydroperoxycyclophosphamide (4HC) for 30 min at 37°C in a water bath. Thereafter, the cells were washed, re-suspended in freezing solution, and cryopreserved using a programmable freezer. The frozen cells were stored in the liquid phase of liquid nitrogen. On the day after bone marrow harvesting the patients began their preparative regimens. Briefly, CY-TBI consisted of cyclophosphamide (CY) 50 mg/kg/day i.v. over 1 h for 4 days, followed by TBI 3 Gy/day for another 4 days. BU-CY consisted of busulfan (BU) 1 mg/kg/dose orally every 6 h for 16 doses (4 days), followed by CY 50 mg/kg/day i.v. over 1 h for another 4 days. All calculations were based on ideal body weight. Intensive i.v. hydration was used as prophylaxis against hemorrhagic cystitis. Bone marrow was infused on the day after completion of CY-TBI, and 24 h after completion of BU-CY. Before administration of the thawed bone marrow, patients were pre-medicated with antihistamines and steroids to minimize the effects of dimethylsulfoxide (DMSO)-mediated histamine release.
CsA was started the day of bone marrow infusion at 1 mg/kg/day i.v. and continued for a minimum of 28 days until the completion of the interferon. CsA dosing was adjusted depending on renal function as described elsewhere. 8, 13 Gamma-interferon-1B (Genentech, San Francisco, CA, USA) 0.05 mg/m 2 s.c., was started after reaching a total white cell count of Ͼ200 cells/ml for 2 consecutive days, and was given subcutaneously every other day for 10 doses.
Evaluation of toxicity and GVHD
The presence of BMT-related toxicities was also evaluated prospectively. Time to absolute neutrophil count (ANC) recovery was defined as number of days from the day of bone marrow infusion until the absolute neutrophil count reached 500 cell/ml or higher on 2 consecutive days. Time to platelet count recovery was defined as number of days from the day of bone marrow infusion until the platelet count reached 50 000 cell/ml or higher on 2 consecutive days.
Patients were evaluated daily for evidence of rash, jaundice, diarrhea and interferon-related toxicities using standard NCI criteria. Serum chemistries, hemogram and stool volumes were evaluated daily. Four-millimeter punch skin biopsies were performed before the beginning of the preparative regimen, and on days 14 and 35 after bone marrow infusion, or at any time if a skin rash suspicious for GVHD developed. Each biopsy was examined by one of the investigators (TH) in a blinded fashion and staged according to standard published criteria. 6, 7 Patients were graded as having GVHD only if there were grade 2 changes in the skin biopsy and a rash. The clinical severity of the skin rash was evaluated by another investigator (VA) also using standard published criteria. 6 Conduct of the trial was approved by the Joint Committee on Clinical Investigation of The Johns Hopkins Hospital. All patients were informed of the risks of transplantation and provided written informed consent.
Statistical methods
Events were measured from the day of bone marrow infusion until the date of death, relapse or last follow-up. The intervals were obtained from data censored on or before 12 February 1998. Event-free survival was estimated by the Kaplan-Meier method, differences between patients who developed auto-GVHD, and those who did not were evaluated by the log-rank test.
Results
From March 1994 to November 1994, 16 patients were entered on the gamma-interferon/CsA trial. The median age was 45 years (range 19-68). The diagnoses included chemo-resistant non-Hodgkin's lymphoma (10), acute lymphoblastic leukemia (two -one in ER 2 and one Ph + ALL in CR 1), chemo-resistant Hodgkin's disease (two), acute myeloid leukemia (one in ER 3), and multiple myeloma (one in PR). Five patients received busulfan and cyclophosphamide (BU-CY) as the preparative regimen, and 11 patients received cyclophosphamide and total body irradiation (CY-TBI).
All patients were prospectively monitored for any toxicity felt related to the immune therapy. Three patients had fevers that were attributed to gamma-interferon, although other sources of fever were found in all three (line sepsis, pneumonitis, relapsed leukemia). Fevers persisted in all three after gamma-interferon therapy was completed in two patients, or discontinued in one. Using NCI toxicity criteria, the following toxicities were seen: hematologic stage 3 -two patients (discussed below); hepatic stage 2 -one patient (with fatal sepsis), hepatic stage 1 -eight patients; pulmonary stage 3 -one patient (infection); and renal stage 2 -11 patients (all receiving nephrotoxic antibiotics and/or amphotericin). The renal stage 2 and hepatic stage 1 toxicity predated gamma-interferon therapy.
One major toxicity of concern was the effect of gammainterferon on marrow engraftment, especially in patients receiving purged grafts, already known to delay marrow recovery compared to unpurged grafts. In this trial, the median ANC recovery was 25.5 days (range 19-46) and median platelet recovery of 50 000 cells/ml was range 40.5 days (range 28-279).
Four patients died without recovering a platelet count of 50 000 cells/ml. Two of the patients died early, on days 19 and 36 due to gram-positive sepsis, and pneumonitis, respectively. The other two patients had a marked delay in platelet recovery, probably due to an immunologic (both were highly alloimmunized) and production deficit (lack of megakaryocytes on bone marrow biopsy) components.
Only 20% of the patients developed a clinically significant rash covering more than 25% of their body with a concomitant positive skin biopsy at a median of day 32 post BMT. The autologous GVHD was mild cutaneous disease in all cases and required no therapy.
Median follow-up for the trial is 964 days as of 6 March 1998 (range 9-1441 days). There were nine deaths in the clinical trial. Two of the deaths were related to transplantation toxicity (infection), while the other seven deaths were due to relapse. One patient died of pneumonitis on day 36 post transplant (thought to be to fungal infection); the other patient died of gram-positive sepsis with acute respiratory distress syndrome and multiple organ failure 19 days post transplant.
Event-free survival is 44%. The relapses were usually within 6 months of BMT with the latest relapse 15 months post BMT. All patients who relapsed have died of disease. Figure 1 shows survival of those patients compared to historic controls not receiving cyclosporine and interferon.
Discussion
We have found that cyclosporine and gamma-interferon after autologous BMT are tolerated without significant additional toxicity. The diversity of diseases included in this trial make the effects on disease relapse impossible to ascertain. However, long-term survival appears to be respectable and the results achieved are worthy of further exploration.
The immune modulations explored in this trial reflect many years of laboratory investigation into autologous GVHD. Autologous GVHD is a two-tiered process requiring both the active inhibition of thymic-dependent clonal deletion of T cells and the elimination of mature T cells that have an immunoregulatory effect. Elimination of the peripheral immunoregulatory mature T cells by the preparative regimen provides a permissive environment for the activation of the syngeneic/autologous GVHD effector T cells that have escaped clonal deletion in the thymus through the effects of cyclosporine. These T cells recognize MHC class II determinants. The specificity of the autoreactive lymphocytes appears to be dependent on the peptide derived from the MHC class II invariant chain. Recent studies also suggest that these autoreactive T cells can effectively target and eliminate MHC class II-expressing tumor cells. In vivo, syngeneic GVHD can mediate a significant anti-tumor effect, achieving a 1-2 log tumor cell kill. Administration of gamma-interferon potentiates the anti-tumor effect of syngeneic GVHD, resulting in cure of 40% of the animals. 5 Moreover, these animals are resistant to rechallenge with the tumor cells suggesting that there is concomitant development of specific anti-tumor immunity.
In this trial we have used interferon to try to increase class II expression on tumor cells. In the prior breast cancer trial using the same drug combination, class II expression was increased in skin biopsies after interferon administration. 13 As compared to the current trial, 56% of the 36 breast cancer patients entered on the trial developed GVHD. The use of unpurged grafts in the breast cancer group likely accounts for the greater clinical expression of GVHD. There is a GVL effect in allogeneic transplants even when clinically significant GVHD is not present. Since it is uncertain that post-transplant immune manipulations result in a lower relapse rate, it is not possible to know if clinical manifestations of autologous GVHD need to be present for the anti-tumor GVL effect to occur. The experience in allogeneic transplants would argue against this. In accord are the recent findings of a direct recognition of tumor cells in autologous GVHD with minimal histologic changes.
Other studies have been reported using post-transplant immunotherapy. Ratanatharathorn et al 15 reported on the use of alpha-interferon with cyclosporine induction of autologous GVHD. The trial enrolled 22 patients with a variety of hematologic malignancies on a four arm phase I trial of cyclosporine alone, interferon alone, and two doses of interferon with cyclosporine. The small groups of patients make interpretation hazardous; however, the study did show the feasibility of this approach. Other studies have looked at interferon alone post transplant (as immunotherapy for both relapse and CMV) or as a marrow purging agent in CML. 16, 17 Likewise, IL-2 has been given post transplant as immunotherapy. 18, 19 Although many of these studies have shown tantalizing hints that post-transplant immune manipulations may reduce the relapse rate, a definitive study has not yet been reported. These studies, like the trials reported here were directed at toxicity and feasibility questions.
In this study we have confirmed that gamma-interferon can be given with cyclosporine after autologous transplant with tolerable side-effects and toxicity. The results in terms of survival are not strictly interpretable given the heterogeneous patient population and preparatory regimens. None the less, the survival with over 3 years of follow-up is encouraging. Based on animals studies, the next clinical trial will look at the maximally effective anti-tumor combination of cyclosporine, IL-2 and interferon given after autologous transplant.
